Skip to content
MARKETS / NASDAQ / APVO
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Aptevo Therapeutics Inc. APVO

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-26.0M
In brief

What this company does

We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. All eight molecules were developed using our proprietary ADAPTIR™ and ADAPTIR-FLEX™ protein technology platforms. We wholly own both platforms. We have successfully designed and constructed numerous therapeutic candidates based on our ADAPTIR platform, which is designed to generate monospecific and bispecific immunotherapeutic proteins that specifically bind to one or more targets.

Written from the business description in Aptevo Therapeutics Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2022 · Revenue 3.1 · Net income 8.0
20M-40M-80M201520172019202120232025
Compound annual growth
−54.2%
−26.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −26.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2022 · Operating -919.7% · Net 257.8%
100%200%-500%-1000%201520172019202120232025
ROE
FY2025 · ROE -234.6%
50%-100%-200%-300%201520172019202120232025

Each USD of equity lost 235 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -21.1
-20M-40M201520172019202120232025

Total assetsUSD 27.2M
EquityUSD 17.4M
CashUSD 21.6M
Current ratio3.82×

Equity funds 64% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B···0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1
Income tax $B0.0·······−0.0−0.0−0.0
Net income $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.10.0−0.1−0.1
Free cash flow $B···−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.1
EPS, diluted $−87.27−31460.23−2316.831.57−6.07−5.23−13.86−2.390.33−5.55−2.93
Dividend / sh $···········
Payout %···········
ROE %−234.6−284.3−115.383.7−319.6−124.8−191.5−95.510.5−161.5−66.9
Shares out B0.000.000.000.010.000.000.000.020.020.020.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 44 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 46 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image